Global GalNAc-siRNA Conjugates Drug Market Growth (Status and Outlook) 2026-2032
The global GalNAc-siRNA Conjugates Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
GalNAc-siRNA conjugates are polysaccharide-siRNA monoconjugates formed by covalently fixing N-acetylated galactosamine (GalNAc) in a trivalent state to the 3' end of the right strand of siRNA of different sequences. GalNAc is a targeting ligand of sialic acid receptor (ASGPR) with high affinity and rapid internalization to liver surface cells, enabling such siRNA conjugates to specifically bind to membrane proteins and enter the cytosol. GalNAc conjugation modification is currently the most commonly used small nucleic acid drug delivery system and has excellent potential in the treatment of liver-related diseases involving gene overexpression. GalNAc conjugates have largely replaced lipid nanoparticles (LNP) for siRNA delivery for liver-targeted diseases. Therefore, drugs based on GalNAc-siRNA conjugates have bright application prospects in cardiovascular diseases, metabolic diseases, and neurological diseases.
United States market for GalNAc-siRNA Conjugates Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for GalNAc-siRNA Conjugates Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for GalNAc-siRNA Conjugates Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key GalNAc-siRNA Conjugates Drug players cover Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Alnylam Pharmaceuticals, Arrowhead, Novo Nordisk (Dicerna), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “GalNAc-siRNA Conjugates Drug Industry Forecast” looks at past sales and reviews total world GalNAc-siRNA Conjugates Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected GalNAc-siRNA Conjugates Drug sales for 2026 through 2032. With GalNAc-siRNA Conjugates Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GalNAc-siRNA Conjugates Drug industry.
This Insight Report provides a comprehensive analysis of the global GalNAc-siRNA Conjugates Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on GalNAc-siRNA Conjugates Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GalNAc-siRNA Conjugates Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GalNAc-siRNA Conjugates Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GalNAc-siRNA Conjugates Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of GalNAc-siRNA Conjugates Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
The report requires updating with new data and is sent in 48 hours after order is placed.
GalNAc-siRNA conjugates are polysaccharide-siRNA monoconjugates formed by covalently fixing N-acetylated galactosamine (GalNAc) in a trivalent state to the 3' end of the right strand of siRNA of different sequences. GalNAc is a targeting ligand of sialic acid receptor (ASGPR) with high affinity and rapid internalization to liver surface cells, enabling such siRNA conjugates to specifically bind to membrane proteins and enter the cytosol. GalNAc conjugation modification is currently the most commonly used small nucleic acid drug delivery system and has excellent potential in the treatment of liver-related diseases involving gene overexpression. GalNAc conjugates have largely replaced lipid nanoparticles (LNP) for siRNA delivery for liver-targeted diseases. Therefore, drugs based on GalNAc-siRNA conjugates have bright application prospects in cardiovascular diseases, metabolic diseases, and neurological diseases.
United States market for GalNAc-siRNA Conjugates Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for GalNAc-siRNA Conjugates Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for GalNAc-siRNA Conjugates Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key GalNAc-siRNA Conjugates Drug players cover Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Alnylam Pharmaceuticals, Arrowhead, Novo Nordisk (Dicerna), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “GalNAc-siRNA Conjugates Drug Industry Forecast” looks at past sales and reviews total world GalNAc-siRNA Conjugates Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected GalNAc-siRNA Conjugates Drug sales for 2026 through 2032. With GalNAc-siRNA Conjugates Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GalNAc-siRNA Conjugates Drug industry.
This Insight Report provides a comprehensive analysis of the global GalNAc-siRNA Conjugates Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on GalNAc-siRNA Conjugates Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GalNAc-siRNA Conjugates Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GalNAc-siRNA Conjugates Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GalNAc-siRNA Conjugates Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of GalNAc-siRNA Conjugates Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Listing
- Clinical Trial
- Cardiovascular Diseases
- Metabolic Diseases
- Neurological Diseases
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Suzhou Ribo Life Science Co., Ltd
- Sirnaomics
- Alnylam Pharmaceuticals
- Arrowhead
- Novo Nordisk (Dicerna)
- Silence Therapeutics
- Arbutus
- Novartis
- Hitgen (Leaderna Therapeutics Ltd.)
The report requires updating with new data and is sent in 48 hours after order is placed.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GalNAc-siRNA Conjugates Drug Market Size (2021-2032)
2.1.2 GalNAc-siRNA Conjugates Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for GalNAc-siRNA Conjugates Drug by Country/Region (2021, 2025 & 2032)
2.2 GalNAc-siRNA Conjugates Drug Segment by Type
2.2.1 Listing
2.2.2 Clinical Trial
2.2.3 GalNAc-siRNA Conjugates Drug Market Size by Type
2.2.3.1 GalNAc-siRNA Conjugates Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
2.3 GalNAc-siRNA Conjugates Drug Segment by Application
2.3.1 Cardiovascular Diseases
2.3.2 Metabolic Diseases
2.3.3 Neurological Diseases
2.3.4 Other
2.3.5 GalNAc-siRNA Conjugates Drug Market Size by Application
2.3.5.1 GalNAc-siRNA Conjugates Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
3 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE BY PLAYER
3.1 GalNAc-siRNA Conjugates Drug Market Size Market Share by Player
3.1.1 Global GalNAc-siRNA Conjugates Drug Revenue by Player (2021-2026)
3.1.2 Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Player (2021-2026)
3.2 Global GalNAc-siRNA Conjugates Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GALNAC-SIRNA CONJUGATES DRUG BY REGION
4.1 GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026)
4.2 Global GalNAc-siRNA Conjugates Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas GalNAc-siRNA Conjugates Drug Market Size Growth (2021-2026)
4.4 APAC GalNAc-siRNA Conjugates Drug Market Size Growth (2021-2026)
4.5 Europe GalNAc-siRNA Conjugates Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas GalNAc-siRNA Conjugates Drug Market Size by Country (2021-2026)
5.2 Americas GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026)
5.3 Americas GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026)
6.2 APAC GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026)
6.3 APAC GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe GalNAc-siRNA Conjugates Drug Market Size by Country (2021-2026)
7.2 Europe GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026)
7.3 Europe GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GalNAc-siRNA Conjugates Drug by Region (2021-2026)
8.2 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET FORECAST
10.1 Global GalNAc-siRNA Conjugates Drug Forecast by Region (2027-2032)
10.1.1 Global GalNAc-siRNA Conjugates Drug Forecast by Region (2027-2032)
10.1.2 Americas GalNAc-siRNA Conjugates Drug Forecast
10.1.3 APAC GalNAc-siRNA Conjugates Drug Forecast
10.1.4 Europe GalNAc-siRNA Conjugates Drug Forecast
10.1.5 Middle East & Africa GalNAc-siRNA Conjugates Drug Forecast
10.2 Americas GalNAc-siRNA Conjugates Drug Forecast by Country (2027-2032)
10.2.1 United States Market GalNAc-siRNA Conjugates Drug Forecast
10.2.2 Canada Market GalNAc-siRNA Conjugates Drug Forecast
10.2.3 Mexico Market GalNAc-siRNA Conjugates Drug Forecast
10.2.4 Brazil Market GalNAc-siRNA Conjugates Drug Forecast
10.3 APAC GalNAc-siRNA Conjugates Drug Forecast by Region (2027-2032)
10.3.1 China GalNAc-siRNA Conjugates Drug Market Forecast
10.3.2 Japan Market GalNAc-siRNA Conjugates Drug Forecast
10.3.3 Korea Market GalNAc-siRNA Conjugates Drug Forecast
10.3.4 Southeast Asia Market GalNAc-siRNA Conjugates Drug Forecast
10.3.5 India Market GalNAc-siRNA Conjugates Drug Forecast
10.3.6 Australia Market GalNAc-siRNA Conjugates Drug Forecast
10.4 Europe GalNAc-siRNA Conjugates Drug Forecast by Country (2027-2032)
10.4.1 Germany Market GalNAc-siRNA Conjugates Drug Forecast
10.4.2 France Market GalNAc-siRNA Conjugates Drug Forecast
10.4.3 UK Market GalNAc-siRNA Conjugates Drug Forecast
10.4.4 Italy Market GalNAc-siRNA Conjugates Drug Forecast
10.4.5 Russia Market GalNAc-siRNA Conjugates Drug Forecast
10.5 Middle East & Africa GalNAc-siRNA Conjugates Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market GalNAc-siRNA Conjugates Drug Forecast
10.5.2 South Africa Market GalNAc-siRNA Conjugates Drug Forecast
10.5.3 Israel Market GalNAc-siRNA Conjugates Drug Forecast
10.5.4 Turkey Market GalNAc-siRNA Conjugates Drug Forecast
10.6 Global GalNAc-siRNA Conjugates Drug Forecast by Type (2027-2032)
10.7 Global GalNAc-siRNA Conjugates Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market GalNAc-siRNA Conjugates Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Suzhou Ribo Life Science Co., Ltd
11.1.1 Suzhou Ribo Life Science Co., Ltd Company Information
11.1.2 Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Product Offered
11.1.3 Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Suzhou Ribo Life Science Co., Ltd Main Business Overview
11.1.5 Suzhou Ribo Life Science Co., Ltd Latest Developments
11.2 Sirnaomics
11.2.1 Sirnaomics Company Information
11.2.2 Sirnaomics GalNAc-siRNA Conjugates Drug Product Offered
11.2.3 Sirnaomics GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Sirnaomics Main Business Overview
11.2.5 Sirnaomics Latest Developments
11.3 Alnylam Pharmaceuticals
11.3.1 Alnylam Pharmaceuticals Company Information
11.3.2 Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Product Offered
11.3.3 Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Alnylam Pharmaceuticals Main Business Overview
11.3.5 Alnylam Pharmaceuticals Latest Developments
11.4 Arrowhead
11.4.1 Arrowhead Company Information
11.4.2 Arrowhead GalNAc-siRNA Conjugates Drug Product Offered
11.4.3 Arrowhead GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Arrowhead Main Business Overview
11.4.5 Arrowhead Latest Developments
11.5 Novo Nordisk (Dicerna)
11.5.1 Novo Nordisk (Dicerna) Company Information
11.5.2 Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Product Offered
11.5.3 Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Novo Nordisk (Dicerna) Main Business Overview
11.5.5 Novo Nordisk (Dicerna) Latest Developments
11.6 Silence Therapeutics
11.6.1 Silence Therapeutics Company Information
11.6.2 Silence Therapeutics GalNAc-siRNA Conjugates Drug Product Offered
11.6.3 Silence Therapeutics GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Silence Therapeutics Main Business Overview
11.6.5 Silence Therapeutics Latest Developments
11.7 Arbutus
11.7.1 Arbutus Company Information
11.7.2 Arbutus GalNAc-siRNA Conjugates Drug Product Offered
11.7.3 Arbutus GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Arbutus Main Business Overview
11.7.5 Arbutus Latest Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis GalNAc-siRNA Conjugates Drug Product Offered
11.8.3 Novartis GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Novartis Main Business Overview
11.8.5 Novartis Latest Developments
11.9 Hitgen (Leaderna Therapeutics Ltd.)
11.9.1 Hitgen (Leaderna Therapeutics Ltd.) Company Information
11.9.2 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Product Offered
11.9.3 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Hitgen (Leaderna Therapeutics Ltd.) Main Business Overview
11.9.5 Hitgen (Leaderna Therapeutics Ltd.) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GalNAc-siRNA Conjugates Drug Market Size (2021-2032)
2.1.2 GalNAc-siRNA Conjugates Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for GalNAc-siRNA Conjugates Drug by Country/Region (2021, 2025 & 2032)
2.2 GalNAc-siRNA Conjugates Drug Segment by Type
2.2.1 Listing
2.2.2 Clinical Trial
2.2.3 GalNAc-siRNA Conjugates Drug Market Size by Type
2.2.3.1 GalNAc-siRNA Conjugates Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
2.3 GalNAc-siRNA Conjugates Drug Segment by Application
2.3.1 Cardiovascular Diseases
2.3.2 Metabolic Diseases
2.3.3 Neurological Diseases
2.3.4 Other
2.3.5 GalNAc-siRNA Conjugates Drug Market Size by Application
2.3.5.1 GalNAc-siRNA Conjugates Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
3 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE BY PLAYER
3.1 GalNAc-siRNA Conjugates Drug Market Size Market Share by Player
3.1.1 Global GalNAc-siRNA Conjugates Drug Revenue by Player (2021-2026)
3.1.2 Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Player (2021-2026)
3.2 Global GalNAc-siRNA Conjugates Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GALNAC-SIRNA CONJUGATES DRUG BY REGION
4.1 GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026)
4.2 Global GalNAc-siRNA Conjugates Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas GalNAc-siRNA Conjugates Drug Market Size Growth (2021-2026)
4.4 APAC GalNAc-siRNA Conjugates Drug Market Size Growth (2021-2026)
4.5 Europe GalNAc-siRNA Conjugates Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas GalNAc-siRNA Conjugates Drug Market Size by Country (2021-2026)
5.2 Americas GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026)
5.3 Americas GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026)
6.2 APAC GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026)
6.3 APAC GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe GalNAc-siRNA Conjugates Drug Market Size by Country (2021-2026)
7.2 Europe GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026)
7.3 Europe GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GalNAc-siRNA Conjugates Drug by Region (2021-2026)
8.2 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET FORECAST
10.1 Global GalNAc-siRNA Conjugates Drug Forecast by Region (2027-2032)
10.1.1 Global GalNAc-siRNA Conjugates Drug Forecast by Region (2027-2032)
10.1.2 Americas GalNAc-siRNA Conjugates Drug Forecast
10.1.3 APAC GalNAc-siRNA Conjugates Drug Forecast
10.1.4 Europe GalNAc-siRNA Conjugates Drug Forecast
10.1.5 Middle East & Africa GalNAc-siRNA Conjugates Drug Forecast
10.2 Americas GalNAc-siRNA Conjugates Drug Forecast by Country (2027-2032)
10.2.1 United States Market GalNAc-siRNA Conjugates Drug Forecast
10.2.2 Canada Market GalNAc-siRNA Conjugates Drug Forecast
10.2.3 Mexico Market GalNAc-siRNA Conjugates Drug Forecast
10.2.4 Brazil Market GalNAc-siRNA Conjugates Drug Forecast
10.3 APAC GalNAc-siRNA Conjugates Drug Forecast by Region (2027-2032)
10.3.1 China GalNAc-siRNA Conjugates Drug Market Forecast
10.3.2 Japan Market GalNAc-siRNA Conjugates Drug Forecast
10.3.3 Korea Market GalNAc-siRNA Conjugates Drug Forecast
10.3.4 Southeast Asia Market GalNAc-siRNA Conjugates Drug Forecast
10.3.5 India Market GalNAc-siRNA Conjugates Drug Forecast
10.3.6 Australia Market GalNAc-siRNA Conjugates Drug Forecast
10.4 Europe GalNAc-siRNA Conjugates Drug Forecast by Country (2027-2032)
10.4.1 Germany Market GalNAc-siRNA Conjugates Drug Forecast
10.4.2 France Market GalNAc-siRNA Conjugates Drug Forecast
10.4.3 UK Market GalNAc-siRNA Conjugates Drug Forecast
10.4.4 Italy Market GalNAc-siRNA Conjugates Drug Forecast
10.4.5 Russia Market GalNAc-siRNA Conjugates Drug Forecast
10.5 Middle East & Africa GalNAc-siRNA Conjugates Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market GalNAc-siRNA Conjugates Drug Forecast
10.5.2 South Africa Market GalNAc-siRNA Conjugates Drug Forecast
10.5.3 Israel Market GalNAc-siRNA Conjugates Drug Forecast
10.5.4 Turkey Market GalNAc-siRNA Conjugates Drug Forecast
10.6 Global GalNAc-siRNA Conjugates Drug Forecast by Type (2027-2032)
10.7 Global GalNAc-siRNA Conjugates Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market GalNAc-siRNA Conjugates Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Suzhou Ribo Life Science Co., Ltd
11.1.1 Suzhou Ribo Life Science Co., Ltd Company Information
11.1.2 Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Product Offered
11.1.3 Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Suzhou Ribo Life Science Co., Ltd Main Business Overview
11.1.5 Suzhou Ribo Life Science Co., Ltd Latest Developments
11.2 Sirnaomics
11.2.1 Sirnaomics Company Information
11.2.2 Sirnaomics GalNAc-siRNA Conjugates Drug Product Offered
11.2.3 Sirnaomics GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Sirnaomics Main Business Overview
11.2.5 Sirnaomics Latest Developments
11.3 Alnylam Pharmaceuticals
11.3.1 Alnylam Pharmaceuticals Company Information
11.3.2 Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Product Offered
11.3.3 Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Alnylam Pharmaceuticals Main Business Overview
11.3.5 Alnylam Pharmaceuticals Latest Developments
11.4 Arrowhead
11.4.1 Arrowhead Company Information
11.4.2 Arrowhead GalNAc-siRNA Conjugates Drug Product Offered
11.4.3 Arrowhead GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Arrowhead Main Business Overview
11.4.5 Arrowhead Latest Developments
11.5 Novo Nordisk (Dicerna)
11.5.1 Novo Nordisk (Dicerna) Company Information
11.5.2 Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Product Offered
11.5.3 Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Novo Nordisk (Dicerna) Main Business Overview
11.5.5 Novo Nordisk (Dicerna) Latest Developments
11.6 Silence Therapeutics
11.6.1 Silence Therapeutics Company Information
11.6.2 Silence Therapeutics GalNAc-siRNA Conjugates Drug Product Offered
11.6.3 Silence Therapeutics GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Silence Therapeutics Main Business Overview
11.6.5 Silence Therapeutics Latest Developments
11.7 Arbutus
11.7.1 Arbutus Company Information
11.7.2 Arbutus GalNAc-siRNA Conjugates Drug Product Offered
11.7.3 Arbutus GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Arbutus Main Business Overview
11.7.5 Arbutus Latest Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis GalNAc-siRNA Conjugates Drug Product Offered
11.8.3 Novartis GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Novartis Main Business Overview
11.8.5 Novartis Latest Developments
11.9 Hitgen (Leaderna Therapeutics Ltd.)
11.9.1 Hitgen (Leaderna Therapeutics Ltd.) Company Information
11.9.2 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Product Offered
11.9.3 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Hitgen (Leaderna Therapeutics Ltd.) Main Business Overview
11.9.5 Hitgen (Leaderna Therapeutics Ltd.) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. GalNAc-siRNA Conjugates Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. GalNAc-siRNA Conjugates Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Listing
Table 4. Major Players of Clinical Trial
Table 5. GalNAc-siRNA Conjugates Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 7. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Table 8. GalNAc-siRNA Conjugates Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 10. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Table 11. Global GalNAc-siRNA Conjugates Drug Revenue by Player (2021-2026) & ($ millions)
Table 12. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Player (2021-2026)
Table 13. GalNAc-siRNA Conjugates Drug Key Players Head office and Products Offered
Table 14. GalNAc-siRNA Conjugates Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026) & ($ millions)
Table 18. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Region (2021-2026)
Table 19. Global GalNAc-siRNA Conjugates Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas GalNAc-siRNA Conjugates Drug Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas GalNAc-siRNA Conjugates Drug Market Size Market Share by Country (2021-2026)
Table 23. Americas GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Table 25. Americas GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Table 27. APAC GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC GalNAc-siRNA Conjugates Drug Market Size Market Share by Region (2021-2026)
Table 29. APAC GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe GalNAc-siRNA Conjugates Drug Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe GalNAc-siRNA Conjugates Drug Market Size Market Share by Country (2021-2026)
Table 33. Europe GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of GalNAc-siRNA Conjugates Drug
Table 39. Key Market Challenges & Risks of GalNAc-siRNA Conjugates Drug
Table 40. Key Industry Trends of GalNAc-siRNA Conjugates Drug
Table 41. Global GalNAc-siRNA Conjugates Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global GalNAc-siRNA Conjugates Drug Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global GalNAc-siRNA Conjugates Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global GalNAc-siRNA Conjugates Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Suzhou Ribo Life Science Co., Ltd Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 46. Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Product Offered
Table 47. Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Suzhou Ribo Life Science Co., Ltd Main Business
Table 49. Suzhou Ribo Life Science Co., Ltd Latest Developments
Table 50. Sirnaomics Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 51. Sirnaomics GalNAc-siRNA Conjugates Drug Product Offered
Table 52. Sirnaomics GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Sirnaomics Main Business
Table 54. Sirnaomics Latest Developments
Table 55. Alnylam Pharmaceuticals Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 56. Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Product Offered
Table 57. Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Alnylam Pharmaceuticals Main Business
Table 59. Alnylam Pharmaceuticals Latest Developments
Table 60. Arrowhead Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 61. Arrowhead GalNAc-siRNA Conjugates Drug Product Offered
Table 62. Arrowhead GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Arrowhead Main Business
Table 64. Arrowhead Latest Developments
Table 65. Novo Nordisk (Dicerna) Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 66. Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Product Offered
Table 67. Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Novo Nordisk (Dicerna) Main Business
Table 69. Novo Nordisk (Dicerna) Latest Developments
Table 70. Silence Therapeutics Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 71. Silence Therapeutics GalNAc-siRNA Conjugates Drug Product Offered
Table 72. Silence Therapeutics GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Silence Therapeutics Main Business
Table 74. Silence Therapeutics Latest Developments
Table 75. Arbutus Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 76. Arbutus GalNAc-siRNA Conjugates Drug Product Offered
Table 77. Arbutus GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Arbutus Main Business
Table 79. Arbutus Latest Developments
Table 80. Novartis Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 81. Novartis GalNAc-siRNA Conjugates Drug Product Offered
Table 82. Novartis GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Novartis Main Business
Table 84. Novartis Latest Developments
Table 85. Hitgen (Leaderna Therapeutics Ltd.) Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 86. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Product Offered
Table 87. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Hitgen (Leaderna Therapeutics Ltd.) Main Business
Table 89. Hitgen (Leaderna Therapeutics Ltd.) Latest Developments
Table 1. GalNAc-siRNA Conjugates Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. GalNAc-siRNA Conjugates Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Listing
Table 4. Major Players of Clinical Trial
Table 5. GalNAc-siRNA Conjugates Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 7. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Table 8. GalNAc-siRNA Conjugates Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 10. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Table 11. Global GalNAc-siRNA Conjugates Drug Revenue by Player (2021-2026) & ($ millions)
Table 12. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Player (2021-2026)
Table 13. GalNAc-siRNA Conjugates Drug Key Players Head office and Products Offered
Table 14. GalNAc-siRNA Conjugates Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026) & ($ millions)
Table 18. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Region (2021-2026)
Table 19. Global GalNAc-siRNA Conjugates Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas GalNAc-siRNA Conjugates Drug Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas GalNAc-siRNA Conjugates Drug Market Size Market Share by Country (2021-2026)
Table 23. Americas GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Table 25. Americas GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Table 27. APAC GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC GalNAc-siRNA Conjugates Drug Market Size Market Share by Region (2021-2026)
Table 29. APAC GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe GalNAc-siRNA Conjugates Drug Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe GalNAc-siRNA Conjugates Drug Market Size Market Share by Country (2021-2026)
Table 33. Europe GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of GalNAc-siRNA Conjugates Drug
Table 39. Key Market Challenges & Risks of GalNAc-siRNA Conjugates Drug
Table 40. Key Industry Trends of GalNAc-siRNA Conjugates Drug
Table 41. Global GalNAc-siRNA Conjugates Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global GalNAc-siRNA Conjugates Drug Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global GalNAc-siRNA Conjugates Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global GalNAc-siRNA Conjugates Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Suzhou Ribo Life Science Co., Ltd Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 46. Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Product Offered
Table 47. Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Suzhou Ribo Life Science Co., Ltd Main Business
Table 49. Suzhou Ribo Life Science Co., Ltd Latest Developments
Table 50. Sirnaomics Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 51. Sirnaomics GalNAc-siRNA Conjugates Drug Product Offered
Table 52. Sirnaomics GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Sirnaomics Main Business
Table 54. Sirnaomics Latest Developments
Table 55. Alnylam Pharmaceuticals Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 56. Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Product Offered
Table 57. Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Alnylam Pharmaceuticals Main Business
Table 59. Alnylam Pharmaceuticals Latest Developments
Table 60. Arrowhead Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 61. Arrowhead GalNAc-siRNA Conjugates Drug Product Offered
Table 62. Arrowhead GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Arrowhead Main Business
Table 64. Arrowhead Latest Developments
Table 65. Novo Nordisk (Dicerna) Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 66. Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Product Offered
Table 67. Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Novo Nordisk (Dicerna) Main Business
Table 69. Novo Nordisk (Dicerna) Latest Developments
Table 70. Silence Therapeutics Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 71. Silence Therapeutics GalNAc-siRNA Conjugates Drug Product Offered
Table 72. Silence Therapeutics GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Silence Therapeutics Main Business
Table 74. Silence Therapeutics Latest Developments
Table 75. Arbutus Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 76. Arbutus GalNAc-siRNA Conjugates Drug Product Offered
Table 77. Arbutus GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Arbutus Main Business
Table 79. Arbutus Latest Developments
Table 80. Novartis Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 81. Novartis GalNAc-siRNA Conjugates Drug Product Offered
Table 82. Novartis GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Novartis Main Business
Table 84. Novartis Latest Developments
Table 85. Hitgen (Leaderna Therapeutics Ltd.) Details, Company Type, GalNAc-siRNA Conjugates Drug Area Served and Its Competitors
Table 86. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Product Offered
Table 87. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Hitgen (Leaderna Therapeutics Ltd.) Main Business
Table 89. Hitgen (Leaderna Therapeutics Ltd.) Latest Developments
LIST OF FIGURES
Figure 1. GalNAc-siRNA Conjugates Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global GalNAc-siRNA Conjugates Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. GalNAc-siRNA Conjugates Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. GalNAc-siRNA Conjugates Drug Sales Market Share by Country/Region (2025)
Figure 8. GalNAc-siRNA Conjugates Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Type in 2025
Figure 10. GalNAc-siRNA Conjugates Drug in Cardiovascular Diseases
Figure 11. Global GalNAc-siRNA Conjugates Drug Market: Cardiovascular Diseases (2021-2026) & ($ millions)
Figure 12. GalNAc-siRNA Conjugates Drug in Metabolic Diseases
Figure 13. Global GalNAc-siRNA Conjugates Drug Market: Metabolic Diseases (2021-2026) & ($ millions)
Figure 14. GalNAc-siRNA Conjugates Drug in Neurological Diseases
Figure 15. Global GalNAc-siRNA Conjugates Drug Market: Neurological Diseases (2021-2026) & ($ millions)
Figure 16. GalNAc-siRNA Conjugates Drug in Other
Figure 17. Global GalNAc-siRNA Conjugates Drug Market: Other (2021-2026) & ($ millions)
Figure 18. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Application in 2025
Figure 19. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Player in 2025
Figure 20. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas GalNAc-siRNA Conjugates Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC GalNAc-siRNA Conjugates Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe GalNAc-siRNA Conjugates Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas GalNAc-siRNA Conjugates Drug Value Market Share by Country in 2025
Figure 26. United States GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC GalNAc-siRNA Conjugates Drug Market Size Market Share by Region in 2025
Figure 31. APAC GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Figure 33. China GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe GalNAc-siRNA Conjugates Drug Market Size Market Share by Country in 2025
Figure 40. Europe GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 59. United States GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 63. China GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 67. India GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 70. France GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 71. UK GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 78. Global GalNAc-siRNA Conjugates Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global GalNAc-siRNA Conjugates Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 1. GalNAc-siRNA Conjugates Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global GalNAc-siRNA Conjugates Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. GalNAc-siRNA Conjugates Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. GalNAc-siRNA Conjugates Drug Sales Market Share by Country/Region (2025)
Figure 8. GalNAc-siRNA Conjugates Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Type in 2025
Figure 10. GalNAc-siRNA Conjugates Drug in Cardiovascular Diseases
Figure 11. Global GalNAc-siRNA Conjugates Drug Market: Cardiovascular Diseases (2021-2026) & ($ millions)
Figure 12. GalNAc-siRNA Conjugates Drug in Metabolic Diseases
Figure 13. Global GalNAc-siRNA Conjugates Drug Market: Metabolic Diseases (2021-2026) & ($ millions)
Figure 14. GalNAc-siRNA Conjugates Drug in Neurological Diseases
Figure 15. Global GalNAc-siRNA Conjugates Drug Market: Neurological Diseases (2021-2026) & ($ millions)
Figure 16. GalNAc-siRNA Conjugates Drug in Other
Figure 17. Global GalNAc-siRNA Conjugates Drug Market: Other (2021-2026) & ($ millions)
Figure 18. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Application in 2025
Figure 19. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Player in 2025
Figure 20. Global GalNAc-siRNA Conjugates Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas GalNAc-siRNA Conjugates Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC GalNAc-siRNA Conjugates Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe GalNAc-siRNA Conjugates Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas GalNAc-siRNA Conjugates Drug Value Market Share by Country in 2025
Figure 26. United States GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC GalNAc-siRNA Conjugates Drug Market Size Market Share by Region in 2025
Figure 31. APAC GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Figure 33. China GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe GalNAc-siRNA Conjugates Drug Market Size Market Share by Country in 2025
Figure 40. Europe GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries GalNAc-siRNA Conjugates Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 59. United States GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 63. China GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 67. India GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 70. France GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 71. UK GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
Figure 78. Global GalNAc-siRNA Conjugates Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global GalNAc-siRNA Conjugates Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries GalNAc-siRNA Conjugates Drug Market Size 2027-2032 ($ millions)
